Cargando…
MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans
SARS-CoV-2 antibodies develop within two weeks of infection, but wane relatively rapidly post-infection, raising concerns about whether antibody responses will provide protection upon re-exposure. Here we revisit T-B cooperation as a prerequisite for effective and durable neutralizing antibody respo...
Autores principales: | Castro, Andrea, Ozturk, Kivilcim, Zanetti, Maurizio, Carter, Hannah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781323/ https://www.ncbi.nlm.nih.gov/pubmed/33398284 http://dx.doi.org/10.1101/2020.12.26.424449 |
Ejemplares similares
-
In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses
por: Castro, Andrea, et al.
Publicado: (2021) -
Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern
por: Almanza, Gonzalo, et al.
Publicado: (2022) -
Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
por: Castro, Andrea, et al.
Publicado: (2019) -
Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants
por: Shitaoka, Kiyomi, et al.
Publicado: (2023) -
Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2
por: Chu, Xiaoyu, et al.
Publicado: (2023)